RT Journal Article
SR Electronic
T1 Serum protein profiling reveals a landscape of inflammation and immune signaling in early-stage COVID-19 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.08.20095836
DO 10.1101/2020.05.08.20095836
A1 Hou, Xin
A1 Zhang, Xiaomei
A1 Wu, Xian
A1 Lu, Minya
A1 Wang, Dan
A1 Xu, Meng
A1 Wang, Hongye
A1 Liang, Te
A1 Dai, Jiayu
A1 Duan, Hu
A1 Xu, Yingchun
A1 Yu, Xiaobo
A1 Li, Yongzhe
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.05.08.20095836.abstract
AB Coronavirus disease 2019 (COVID-19) is a highly contagious infection and threating the human lives in the world. The elevation of cytokines in blood is crucial to induce cytokine storm and immunosuppression in the transition of severity in COVID-19 patients. However, the comprehensive changes of serum proteins in COVID-19 patients throughout the SARS-CoV-2 infection is unknown. In this work, we developed a high-density antibody microarray and performed an in-depth proteomics analysis of serum samples collected from early COVID-19 (n=15) and influenza (n=13) patients. We identified a large set of differentially expressed proteins (n=125) that participate in a landscape of inflammation and immune signaling related to the SARS-CoV-2 infection. Furthermore, the significant correlations of neutrophil and lymphocyte with the CCL2 and CXCL10 mediated cytokine signaling pathways was identified. These information are valuable for the understanding of COVID-19 pathogenesis, identification of biomarkers and development of the optimal anti-inflammation therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialZS-2303Funding StatementThis research was supported by grants from the National Natural Science Foundation of China Grants (81671618, 81871302, 81673040, 31870823), CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-3-001, 2017-I2M-B&R-01), the State Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201703, SKLP-K201505), the Beijing Municipal Education Commission and the National Program on Key Basic Research Project (2018YFA0507503, 2017YFC0906703, 2018ZX09733003).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is avaialable upon of requrest.